Twilight Litaka Pharma Peer Comparison
NSE: TWILITAKA | BSE: 506985
₹2.88
₹-0.15
(-4.95%)
As on 01-Jan-2015IST
Market cap
₹7 Cr
Revenue (TTM)
₹13 Cr
P/E Ratio
--
P/B Ratio
-0
Div. Yield
0 %
Edit
| Twilight Litaka Pharma | Wockhardt | Rubicon Research | Acutaas Chemicals | Piramal Pharma | |
|---|---|---|---|---|---|
Market cap (₹ Cr) |
7 | 37,212 | 27,783 | 26,915 | 27,712 |
Revenue (₹ Cr) |
13 | 3,564 | 1,936 | 1,462 | 9,205 |
Net Profit (₹ Cr) |
-147.22 | 414.00 | 288.22 | 387.35 | -371.81 |
Net Margin (%) |
-1,169.22 | 11.23 | 14.79 | 26.01 | -3.93 |
RoE (%) |
-- | 8.38 | 29.77 | 25.18 | -3.85 |
Price to Earnings |
-- | 90.98 | 96.40 | 69.69 | -- |
Price-To-Book |
-0.05 | 7.39 | 20.70 | 15.60 | 3.46 |
Income Statement (₹ Cr)
| Twilight Litaka Pharma | Wockhardt | Rubicon Research | Acutaas Chemicals | Piramal Pharma | |
|---|---|---|---|---|---|
|
Operating Revenue
|
31.50 | 4,830.36 | 41.58 | 76.11 | -- |
|
Total Income
|
31.51 | 4,914.64 | 41.73 | 76.68 | -- |
|
Total Expenditure
|
40.46 | 3,850.53 | 30.00 | 69.99 | -- |
|
EBITDA
|
-8.95 | 979.83 | 11.59 | 6.12 | -- |
|
Depreciation
|
5.39 | 139.92 | 3.35 | 0.80 | -- |
|
EBIT
|
-14.34 | 839.91 | 8.24 | 5.32 | -- |
|
Interest
|
0.41 | 83.35 | 2.34 | 1.58 | -- |
|
Other Income
|
0.00 | 84.28 | 0.14 | 0.56 | -- |
|
Exceptional Items
|
-125.45 | 49.83 | -- | -- | -- |
|
Profit before Tax
|
-140.20 | 890.67 | 6.04 | 4.31 | -- |
|
Provision for Tax
|
1.17 | 47.88 | 1.54 | 1.44 | -- |
|
Profit after Tax
|
-140.20 | 842.79 | 4.50 | 2.86 | -- |
Liabilities (₹ Cr)
| Twilight Litaka Pharma | Wockhardt | Rubicon Research | Acutaas Chemicals | Piramal Pharma | |
|---|---|---|---|---|---|
|
Shareholder's Funds
|
-132.30 | 3,581.47 | 44.83 | 10.77 | -- |
|
Minority Interest
|
-- | 136.17 | -- | -- | -- |
|
Non-Current Liabilities
|
39.25 | 1,161.18 | 10.36 | 1.29 | -- |
|
Current Liabilities
|
424.39 | 1,743.20 | 21.34 | 26.33 | -- |
|
Total Liabilities
|
331.35 | 6,622.02 | 76.53 | 38.71 | -- |
Assets (₹ Cr)
| Twilight Litaka Pharma | Wockhardt | Rubicon Research | Acutaas Chemicals | Piramal Pharma | |
|---|---|---|---|---|---|
|
Non-Current Assets
|
112.86 | 3,266.10 | 51.75 | 7.38 | -- |
|
Current Assets
|
218.48 | 3,355.92 | 24.78 | 31.01 | -- |
|
Total Assets
|
331.35 | 6,622.02 | 76.53 | 38.71 | -- |
|
Total Debt*
|
321.98 | 1,906.08 | 21.09 | 12.17 | -- |
|
Net Current Assets
|
-205.91 | 1,612.72 | 3.44 | 4.68 | -- |
|
Contingent Liabilities
|
107.19 | 267.40 | 4.70 | -- | -- |
Cashflow (₹ Cr)
| Twilight Litaka Pharma | Wockhardt | Rubicon Research | Acutaas Chemicals | Piramal Pharma | |
|---|---|---|---|---|---|
|
Cash From Operating Activities
|
1.52 | 1,476.29 | 6.29 | -0.21 | -- |
|
Cash Flow from Investing Activities
|
-0.36 | -851.62 | -5.46 | -2.00 | -- |
|
Cash from Financing Activities
|
-0.66 | -601.32 | -0.58 | 2.17 | -- |
|
Net Cash Inflow / Outflow
|
0.50 | 23.35 | 0.25 | -0.04 | -- |
Ratios
Profitability Ratios
| Twilight Litaka Pharma | Wockhardt | Rubicon Research | Acutaas Chemicals | Piramal Pharma | |
|---|---|---|---|---|---|
|
ROCE (%)
|
-55.00 | 18.98 | 13.38 | 29.97 | -- |
|
ROE (%)
|
0.00 | 30.04 | 19.08 | 30.26 | -- |
|
ROA (%)
|
-35.44 | 13.36 | 6.16 | 8.85 | -- |
|
EBIT Margin (%)
|
-28.41 | 22.03 | 28.21 | 8.78 | -- |
|
Net Margin (%)
|
-444.96 | 17.15 | 10.78 | 3.74 | -- |
|
Cash Profit Margin (%)
|
-427.90 | 20.32 | 18.86 | 4.81 | -- |
Growth Ratios
| Twilight Litaka Pharma | Wockhardt | Rubicon Research | Acutaas Chemicals | Piramal Pharma | |
|---|---|---|---|---|---|
|
Revenue Growth (%)
|
-90.69 | -13.89 | 12.11 | 37.10 | -- |
|
EBIT Growth (%)
|
80.33 | -49.66 | 21.82 | 30.95 | -- |
|
Net Profit Growth (%)
|
17.99 | -46.64 | 58.36 | 39.55 | -- |
|
EPS Growth (%)
|
17.99 | -56.04 | 58.36 | 39.55 | -- |
|
Book Value Growth (%)
|
-6,435.70 | 36.37 | 21.09 | 32.03 | -- |
Valuation Ratios
| Twilight Litaka Pharma | Wockhardt | Rubicon Research | Acutaas Chemicals | Piramal Pharma | |
|---|---|---|---|---|---|
|
Price / Earnings
|
0.00 | 6.59 | 0.00 | 0.00 | -- |
|
Price / Book Value
|
-0.11 | 1.55 | 0.00 | 0.00 | -- |
|
Dividend Yield (%)
|
0.00 | 2.19 | -- | -- | -- |
|
EV/EBITDA
|
-37.56 | 5.73 | 3.52 | 2.02 | -- |
|
Market Cap (₹ Cr)
|
15.09 | 5,016.58 | 0.00 | 0.00 | -- |
Solvency Ratios
| Twilight Litaka Pharma | Wockhardt | Rubicon Research | Acutaas Chemicals | Piramal Pharma | |
|---|---|---|---|---|---|
|
Debt to Equity
|
-2.33 | 0.54 | 0.47 | 1.13 | -- |
|
Short term debt to equity ratio
|
-1.84 | 0.06 | 0.23 | 0.84 | -- |
|
Current Ratio
|
0.51 | 1.93 | 1.16 | 1.18 | -- |
|
Quick Ratio
|
0.51 | 1.36 | 1.11 | 0.75 | -- |
|
Interest Coverage
|
-341.46 | 11.69 | 3.58 | 3.73 | -- |
Operating Efficiency Ratios
| Twilight Litaka Pharma | Wockhardt | Rubicon Research | Acutaas Chemicals | Piramal Pharma | |
|---|---|---|---|---|---|
|
Debtors to sales (%)
|
663.25 | 9.96 | 33.85 | 17.81 | -- |
|
Asset Turnover
|
0.08 | 0.77 | 0.57 | 2.35 | -- |
|
Receivable days
|
2,740.44 | 54.33 | 106.93 | 58.46 | -- |
|
Inventory Days
|
342.60 | 77.43 | 10.49 | 41.85 | -- |
|
Payable days
|
569.97 | 120.43 | 213.33 | 91.25 | -- |
|
Cash Conversion Cycle
|
2,513.07 | 11.32 | -95.91 | 9.06 | -- |
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
loading...
loading...
loading...
loading...
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.
